Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rüberg S[au]:

Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Mestdagh P et al. Nat Methods. (2014)

Estimands in clinical trials - broadening the perspective. Akacha M et al. Stat Med. (2017)

Considerations for Evaluating Treatment Effects From Randomized Clinical Trials. Ruberg SJ et al. Clin Pharmacol Ther. (2017)

Search results

Items: 1 to 50 of 53

1.

Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Tian L, Fu H, Ruberg SJ, Uno H, Wei LJ.

Biometrics. 2018 Jun;74(2):694-702. doi: 10.1111/biom.12770. Epub 2017 Sep 12.

2.

Considerations for Evaluating Treatment Effects From Randomized Clinical Trials.

Ruberg SJ, Akacha M.

Clin Pharmacol Ther. 2017 Dec;102(6):917-923. doi: 10.1002/cpt.869. Epub 2017 Oct 9.

PMID:
28891044
3.

Novel Large Sulfur Bacteria in the Metagenomes of Groundwater-Fed Chemosynthetic Microbial Mats in the Lake Huron Basin.

Sharrar AM, Flood BE, Bailey JV, Jones DS, Biddanda BA, Ruberg SA, Marcus DN, Dick GJ.

Front Microbiol. 2017 May 8;8:791. doi: 10.3389/fmicb.2017.00791. eCollection 2017.

4.

Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement.

Giménez-Arnau A, Curto-Barredo L, Nonell L, Puigdecanet E, Yelamos J, Gimeno R, Rüberg S, Santamaria-Babi L, Pujol RM.

Allergy. 2017 Nov;72(11):1778-1790. doi: 10.1111/all.13183. Epub 2017 May 26.

PMID:
28407332
5.

Diverse manganese(II)-oxidizing bacteria are prevalent in drinking water systems.

Marcus DN, Pinto A, Anantharaman K, Ruberg SA, Kramer EL, Raskin L, Dick GJ.

Environ Microbiol Rep. 2017 Apr;9(2):120-128. doi: 10.1111/1758-2229.12508. Epub 2017 Jan 25.

6.

Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells.

Agorku DJ, Tomiuk S, Klingner K, Wild S, Rüberg S, Zatrieb L, Bosio A, Schueler J, Hardt O.

J Vis Exp. 2016 Jul 29;(113). doi: 10.3791/54259.

7.

Estimands in clinical trials - broadening the perspective.

Akacha M, Bretz F, Ruberg S.

Stat Med. 2017 Jan 15;36(1):5-19. doi: 10.1002/sim.7033. Epub 2016 Jul 19.

PMID:
27435045
8.

The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.

Aloia A, Petrova E, Tomiuk S, Bissels U, Déas O, Saini M, Zickgraf FM, Wagner S, Spaich S, Sütterlin M, Schneeweiss A, Reitberger M, Rüberg S, Gerstmayer B, Agorku D, Knöbel S, Terranegra A, Falleni M, Soldati L, Sprick MR, Trumpp A, Judde JG, Bosio A, Cairo S, Hardt O.

Breast Cancer Res. 2015 Nov 25;17(1):146. doi: 10.1186/s13058-015-0652-6.

9.

Making what's advanced today routine tomorrow.

Ruberg SJ.

J Biopharm Stat. 2016;26(1):55-70. doi: 10.1080/10543406.2015.1092035. Review.

PMID:
26397979
10.

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.

Lindborg SR, Persinger CC, Sashegyi A, Mallinckrodt C, Ruberg SJ.

Nat Rev Drug Discov. 2014 Aug;13(8):638-40. doi: 10.1038/nrd3681-c1. No abstract available.

PMID:
25082289
11.

Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study.

Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, Cheo D, D'Andrade P, DeMayo M, Dennis L, Derveaux S, Feng Y, Fulmer-Smentek S, Gerstmayer B, Gouffon J, Grimley C, Lader E, Lee KY, Luo S, Mouritzen P, Narayanan A, Patel S, Peiffer S, Rüberg S, Schroth G, Schuster D, Shaffer JM, Shelton EJ, Silveria S, Ulmanella U, Veeramachaneni V, Staedtler F, Peters T, Guettouche T, Wong L, Vandesompele J.

Nat Methods. 2014 Aug;11(8):809-15. doi: 10.1038/nmeth.3014. Epub 2014 Jun 29. Erratum in: Nat Methods. 2014 Sep;11(9):971.

PMID:
24973947
12.

Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models.

Fu H, Price KL, Nilsson ME, Ruberg SJ.

J Biopharm Stat. 2013;23(1):26-42. doi: 10.1080/10543406.2013.735761.

PMID:
23331219
13.

A portfolio-based approach to optimize proof-of-concept clinical trials.

Mallinckrodt C, Molenberghs G, Persinger C, Ruberg S, Sashegyi A, Lindborg S.

J Biopharm Stat. 2012;22(3):596-607. doi: 10.1080/10543406.2011.564340. Erratum in: J Biopharm Stat. 2016;26(5):1005.

PMID:
22416843
14.

Subgroup identification from randomized clinical trial data.

Foster JC, Taylor JM, Ruberg SJ.

Stat Med. 2011 Oct 30;30(24):2867-80. doi: 10.1002/sim.4322. Epub 2011 Aug 4.

15.

Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia.

Wang F, Ruberg SJ, Gaynor PJ, Heinloth AN, Arnold LM.

J Pain. 2011 Oct;12(10):1088-94. doi: 10.1016/j.jpain.2011.05.002. Epub 2011 Jul 18.

PMID:
21763211
16.

Nuclear outsourcing of RNA interference components to human mitochondria.

Bandiera S, Rüberg S, Girard M, Cagnard N, Hanein S, Chrétien D, Munnich A, Lyonnet S, Henrion-Caude A.

PLoS One. 2011;6(6):e20746. doi: 10.1371/journal.pone.0020746. Epub 2011 Jun 13.

17.

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.

Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ.

BMC Psychiatry. 2011 Feb 9;11:23. doi: 10.1186/1471-244X-11-23.

18.

The mean does not mean as much anymore: finding sub-groups for tailored therapeutics.

Ruberg SJ, Chen L, Wang Y.

Clin Trials. 2010 Oct;7(5):574-83. doi: 10.1177/1740774510369350. Epub 2010 Jul 28.

PMID:
20667935
19.

Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients.

Block SL, Williams D, Donnelly CL, Dunn DW, Saylor KE, Ruberg SJ.

Clin Pediatr (Phila). 2010 Aug;49(8):768-76. doi: 10.1177/0009922810368134. Epub 2010 Jun 3.

PMID:
20522617
20.

Raising the bar of efficacy for drug approval requires an understanding of patient diversity.

Berger ML, Eck S, Ruberg SJ.

J Clin Oncol. 2010 Jul 10;28(20):e343-4; author reply e345. doi: 10.1200/JCO.2010.28.2475. Epub 2010 May 10. No abstract available.

PMID:
20458030
21.

Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.

Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S.

Schizophr Res. 2009 Aug;113(1):34-40. doi: 10.1016/j.schres.2009.06.001. Epub 2009 Jun 28.

PMID:
19564097
22.

A portal for rhizobial genomes: RhizoGATE integrates a Sinorhizobium meliloti genome annotation update with postgenome data.

Becker A, Barnett MJ, Capela D, Dondrup M, Kamp PB, Krol E, Linke B, Rüberg S, Runte K, Schroeder BK, Weidner S, Yurgel SN, Batut J, Long SR, Pühler A, Goesmann A.

J Biotechnol. 2009 Mar 10;140(1-2):45-50. doi: 10.1016/j.jbiotec.2008.11.006. Epub 2008 Dec 6.

23.

ICH-E9 reflections and considerations.

Rockhold FW, Ruberg SJ.

Pharm Stat. 2008 Oct-Dec;7(4):233-5. doi: 10.1002/pst.345. No abstract available.

PMID:
18767057
24.

Fine-tuning of galactoglucan biosynthesis in Sinorhizobium meliloti by differential WggR (ExpG)-, PhoB-, and MucR-dependent regulation of two promoters.

Bahlawane C, Baumgarth B, Serrania J, Rüberg S, Becker A.

J Bacteriol. 2008 May;190(10):3456-66. doi: 10.1128/JB.00062-08. Epub 2008 Mar 14.

25.

Partition testing in dose-response studies with multiple endpoints.

Liu Y, Hsu J, Ruberg S.

Pharm Stat. 2007 Jul-Sep;6(3):181-92.

PMID:
17654696
26.

Two new Sinorhizobium meliloti LysR-type transcriptional regulators required for nodulation.

Luo L, Yao SY, Becker A, Rüberg S, Yu GQ, Zhu JB, Cheng HP.

J Bacteriol. 2005 Jul;187(13):4562-72.

27.

Wide-range transcriptional modulating effect of ntrR under microaerobiosis in Sinorhizobium meliloti.

Puskás LG, Nagy ZB, Kelemen JZ, Rüberg S, Bodogai M, Becker A, Dusha I.

Mol Genet Genomics. 2004 Oct;272(3):275-89. Epub 2004 Sep 9.

PMID:
15365818
28.

Sinorhizobium meliloti ExoR and ExoS proteins regulate both succinoglycan and flagellum production.

Yao SY, Luo L, Har KJ, Becker A, Rüberg S, Yu GQ, Zhu JB, Cheng HP.

J Bacteriol. 2004 Sep;186(18):6042-9.

29.

Global changes in gene expression in Sinorhizobium meliloti 1021 under microoxic and symbiotic conditions.

Becker A, Bergès H, Krol E, Bruand C, Rüberg S, Capela D, Lauber E, Meilhoc E, Ampe F, de Bruijn FJ, Fourment J, Francez-Charlot A, Kahn D, Küster H, Liebe C, Pühler A, Weidner S, Batut J.

Mol Plant Microbe Interact. 2004 Mar;17(3):292-303.

30.

Construction and validation of a Sinorhizobium meliloti whole genome DNA microarray: genome-wide profiling of osmoadaptive gene expression.

Rüberg S, Tian ZX, Krol E, Linke B, Meyer F, Wang Y, Pühler A, Weidner S, Becker A.

J Biotechnol. 2003 Dec 19;106(2-3):255-68.

PMID:
14651866
31.

Regulation of succinoglycan and galactoglucan biosynthesis in Sinorhizobium meliloti.

Becker A, Rüberg S, Baumgarth B, Bertram-Drogatz PA, Quester I, Pühler A.

J Mol Microbiol Biotechnol. 2002 May;4(3):187-90. Review.

PMID:
11931545
32.

Strategy to sequence the genome of Corynebacterium glutamicum ATCC 13032: use of a cosmid and a bacterial artificial chromosome library.

Tauch A, Homann I, Mormann S, Rüberg S, Billault A, Bathe B, Brand S, Brockmann-Gretza O, Rückert C, Schischka N, Wrenger C, Hoheisel J, Möckel B, Huthmacher K, Pfefferle W, Pühler A, Kalinowski J.

J Biotechnol. 2002 Apr 25;95(1):25-38.

PMID:
11879709
33.

Paradigm shifts in clinical trials enabled by information technology.

Marks RG, Conlon M, Ruberg SJ.

Stat Med. 2001 Sep 15-30;20(17-18):2683-96.

PMID:
11523076
34.

Detecting dose response with contrasts.

Stewart WH, Ruberg SJ.

Stat Med. 2000 Apr 15;19(7):913-21.

PMID:
10750059
36.

Providing evidence of efficacy for a new drug.

Ruberg S, Cairns V.

Stat Med. 1998 Aug 15-30;17(15-16):1813-23; discussion 1825-7. Review.

PMID:
9749449
37.

The regulatory protein MucR binds to a short DNA region located upstream of the mucR coding region in Rhizobium meliloti.

Bertram-Drogatz PA, Rüberg S, Becker A, Pühler A.

Mol Gen Genet. 1997 May 20;254(5):529-38.

PMID:
9197412
38.

The 32-kilobase exp gene cluster of Rhizobium meliloti directing the biosynthesis of galactoglucan: genetic organization and properties of the encoded gene products.

Becker A, Rüberg S, Küster H, Roxlau AA, Keller M, Ivashina T, Cheng HP, Walker GC, Pühler A.

J Bacteriol. 1997 Feb;179(4):1375-84.

39.
40.

Factorial dose-response studies using frequency and magnitude of dose.

Hafner KB, Ruberg SJ.

J Biopharm Stat. 1996 Jul;6(3):253-62.

PMID:
8854230
41.

Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability.

Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L.

Am Heart J. 1996 Mar;131(3):472-80.

PMID:
8604626
43.

Dose response studies. II. Analysis and interpretation.

Ruberg SJ.

J Biopharm Stat. 1995 Mar;5(1):15-42. Review. Erratum in: J Biopharm Stat 1996 Jul;6(3):375.

PMID:
7613559
44.

Dose response studies. I. Some design considerations.

Ruberg SJ.

J Biopharm Stat. 1995 Mar;5(1):1-14. Review.

PMID:
7613556
45.

Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1.

Smithers JA, Thompson GA, Kenny MT, Dulworth JK, Kulmala HK, Lewis EW, Ruberg SJ, Shapiro BE, Keane WF, Halstenson CE.

Biopharm Drug Dispos. 1992 Nov;13(8):571-81.

PMID:
1421051
46.

Pharmacokinetics of terfenadine in healthy elderly subjects.

Eller MG, Walker BJ, Westmark PA, Ruberg SJ, Antony KK, McNutt BE, Okerholm RA.

J Clin Pharmacol. 1992 Mar;32(3):267-71.

PMID:
1564131
47.

Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.

Smithers JA, Kulmala HK, Thompson GA, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA.

Antimicrob Agents Chemother. 1992 Jan;36(1):115-20.

48.

Pooling data for stability studies: testing the equality of batch degradation slopes.

Ruberg SJ, Stegeman JW.

Biometrics. 1991 Sep;47(3):1059-69.

PMID:
1742430
49.

Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R.

Antimicrob Agents Chemother. 1990 May;34(5):765-9.

50.

Hemodynamic effects of a constant intravenous infusion of piroximone in patients with severe congestive heart failure.

Miller WE, Kennedy GT, Ruberg SJ, O'Rourke RA, Crawford MH.

J Cardiovasc Pharmacol. 1988 Jul;12(1):72-7.

PMID:
2459538

Supplemental Content

Loading ...
Support Center